Metabolic disorders are a relatively uncommon, but important, cause of childhood seizures. Routinely searching for a metabolic disorder in epilepsy is usually unrewarding. Children and adolescents with epilepsy can be selected for appropriate biochemical investigation by considering the seizure type, age of onset, EEG appearance, family history, clinical findings and the results of brain imaging. A limited number of biochemical screening tests can be used to categorize the more common metabolic disorders associated with seizures.
INTRODUCTION
Although a large number of biochemical or metabolic disorders may be associated with seizures, the vast majority of children and adolescents with epilepsy do not have any demonstrable metabolic abnormality.
However, it is important to consider the possibility that epilepsy may be caused by an underlying metabolic disorder because of the genetic implications of such conditions. Furthermore, the epilepsy and any associated neurological dysfunction could be resolved with appropriate management of the underlying metabolic disturbance.
Metabolic disorders cause seizures through a number of mechanisms'; electrolyte disturbances alter the electrical properties of neuronal membranes; disorders of intermediary metabolism may severely disrupt the sources of energy available for neuronal function or affect neuro-transmitter levels and the abnormal accumulation of intracellular macromolecules can alter the electrical properties of neurones by disrupting the cellular membrane which ultimately leads to cell death. Each of these mechanisms may be active singly, or in varying combinations, in any given metabolic disorder that causes seizures.
Performing a routine biochemical 'screen' in order to detect a possible underlying metabolic disorder in all children and adolescents presenting with seizures is usually an unrewarding and therefore unnecessary exercise2v3. Instead, a selective approach to the biochemical investigation of epilepsy is required and for this the clinician needs to know when to suspect an underlying metabolic disorder and how to investigate and treat the presumed metabolic problem. This article will discuss a practical approach to the detection of metabolic disorders that may cause epilepsy. The treatment of these disorders will then be briefly considered.
When managing epilepsy in childhood, the seizure type and, if possible, the epilepsy syndrome should be identified in order to select the most appropriate treatment4. Recognition of an epilepsy syndrome also increases the accuracy of prognosis for an individual's epilepsy. Epilepsy syndromes are defined by the seizure type, age of seizure onset, EEG findings and associated features such as family history, clinical findings and the results of imaging studiessT6. Conveniently, these same categories can also be considered when determining the likelihood of an underlying metabolic disorder in an infant, child or adolescent with epilepsy.
SEIZURE TYPE
There is no single seizure type that is invariably associated with an underlying disorder of metabolism. Although myoclonic seizures, particularly erratic or fragmentary myoclonic seizures, are relatively more common in patients with metabolic disorders, most children and adolescents who exhibit myoclonic seizures do not have a metabolic disease7. As well as causing 'non-specific' myoclonic seizures, metabolic diseases are associated with a particular group of myoclonic epilepsies known as the 'progressive myoclonus epilepsies' in which frequent and severe myoclonic seizures are usually associated with progressive neurological dysfunction that usually includes ataxia and dementia'.
Infantile spasms are not commonly caused by metabolic disorders, now that most patients with phenylketonuria receive early dietary treatment following the introduction of neonatal screening. Infantile spasms have occasionally been described in infants with pyridoxine dependency, biotinidase deficiency, non-ketotic hyperglycinaemia, Leigh's disease, Alpers' disease, Menkes disease, Krabbe disease and neonatal adrenoleukodystrophy'.
Although myoclonic seizures are relatively more common in metabolic disorders, any other seizure type can occur. Furthermore, severe metabolic derangements might be expected to cause global cerebral dysfunction resulting in generalized seizures, but in fact partial seizure are not uncommon'"*'l.
Recognizing epileptic seizures can be particularly difficult in the neonatal period and this applies equally to seizures associated with metabolic disturbances. For example, massive myoclonus and repeated, brief tonic-clonic seizures in an infant with biotinidase deficiency", and some of the erratic, massive myoclonic jerks in several infants with non-ketotic hyperglycinaemia'3, were shown to be non-epileptic on detailed neurophysiological investigation.
AGE OF ONSET
There are a large number of metabolic disorders that affect the nervous system in the neonatal period14, and during later childhoodi5. These disorders can be broadly classified according to the age of onset of clinical manifestations?.
With the possible exceptions of pyridoxine dependency, non-ketotic hyperglycinaemia and sulphite oxidase deficiency, metabolic disorders do not invariably cause seizures. However, certain metabolic disorders are typically associated with seizures and the usual age of onset of seizures in each of these disorders is shown in Hypocalcaemia tends to occur during the first 3 days of life in low-birth-weight infants and infants of diabetic mothers, or later in the neonatal period if incorrect quantities of calcium and phosphate are given in enteral or parental feeds. Severely disordered sodium and water balance leading to seizures usually results from conditions associated with inappropriate secretion of antidiuretic hormone, or from inappropriate salt and water replacement therapy.
Disorders of intermediary metabolism are most likely to present abruptly in the neonatal period, although some of these disorders can occur episodically during childhood, often in association with infective illnesses, stress (including trauma) or, in some cases, following an unusually high protein intake. Metabolic storage and degenerative disorders tend to develop more insidiously later in infancy or during childhood.
EEG FINDINGS
There are no specific EEG findings that are invariably associated with metabolic diseases. Certain EEG appearances are characteristic of particular disorders of metabolism but are not necessarily exclusive to these disorders.
The biochemical investigation of epilepsy in childhood An 'hypsarrhythmiclike' EEG may be seen in pyridoxine dependency and because of this some clinicians recommend giving intravenous pyridoxine to all infants who present with newly diagnosed infantile spasms, during their initial EEG; however, using this protocol, the positive identification of genuine pyridoxine dependency would appear to be extremely low (personal data and communications).
The neuronal ceroid lipofuscinoses comprises a group of lipopigment storage diseases with a presumed metabolic basis. The EEG findings contribute towards the identification of the different disease groups, with the most striking appearance occurring in the late infantile form of the disease where low-rate photic stimulation (usually at one flash per second) produces a large amplitude response, similar to the appearance of a visual evoked potential*'.
A variety of EEG changes may be found in mitochondrial disorders but, as the disease progresses, the EEG in most subjects eventually shows a marked slowing of the background alpha rhythm*'.
A number of metabolic disturbances have been reported in progressive neuronal degeneration of childhood with liver disease (Alpers' disease), including mitochondrial disorders**. Once seizures becme established in this disorder, the EEG frequently comprises very slow (4 Hz), high amplitude activity with superimposed low amplitude polyspikes23, which may be focal or generalized. This activity (which is not specific for Alpers' disease) is often termed 'PLEDs' (periodic lateralizing epileptiform discharges).
FAMILY HISTORY
Parental consanguinity increases the risk of an inborn error of metabolism since most are recessively inherited. In contrast, mitochondria are maternally inherited, and so when epilepsy, especially myoclonic epilepsy, appears to be transmitted through the female side of a family then a mitochondrial disorder may be responsible for the seizures. The currently identified mitochondrial disorders which are particularly associated with seizures include 'MERRF'
[myoclonic epilepsy with ragged red fibres (seen on muscle biopsy)] and 'MELAS' (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes). Finally, an underlying metabolic disorder should be considered in any child with 7 epilepsy who has a sibling that suffered an unexplained death. and severe, childhood-onset adrenoleucodystrophy (increased levels of very long chain fatty acids in plasma and cultured skin fibroblasts). Cerebral calcification, readily demonstrated on computerized tomography (CT) but far less well shown on magnetic resonance imaging (MRI) may also provide aetiological clues including coeliac disease (predominantly involving the occipital cortex) and parathyroid dysfunction, a mitochondrial cytopathy and deficiencies of biotinidase and biopterins (primarily involving the basal ganglia). Importantly, certain structural abnormalites may also be found in subjects with metabolic disorders; specifically agenesis or hypoplasia of the corpus collosum, sometimes in association with other brain malformations, has been described in non-ketotic hyperglycinaemia, Zellweger syndrome, histidinaemia, pyruvate carboxylase deficiency and pyruvate dehydrogenase deficiency4. Localized thinning of the corpus collosum and a veriety of other cerebral malformations have also been noted in early onset pyridoxine dependency35. These brain malformations and the dysmorphic features described earlier indicate the adverse effect of some metabolic disorders on foetal development, and have obvious implications for the investigation of children with seizures who are found to have cerebral dysgenesis, particularly if it involves the corpus callosum. If the child's overall clinical (includinng the neurological) status cannot be explained solely by dysgenesis of the corpus callosum, then an underlying metabolic abnormality should be considered, and sought.
BIOCHEMICAL INVESTIGATIONS
Blood glucose, calcium and magnesium should be checked in all children and adolescents with seizures in whom a metabolic disorder is suspected. The investigation and management of the less common disorders of metabolism that may be associated with epilepsy requires liaison with staff at a reference biochemistry laboratory, a paediatrician with an interest in metabolic disorders and a paediatric neurologist. Several useful schemes for investigating metabolic disorders have been published1*14*36,37. In patients presenting with an acute encephalopathy associated with seizures it should be possible to categorize broadly any underlying disorder of intermediary metabolism using a few 'screening' biochemical investigations which will be available in most hospitals as shown (Table 2) , however, these screening tests will all be negative in a few disorders as indicated at the end of Table 2 .
Further biochemical investigation will be required to help diagnose the specific intermediary metabolic disorder which usually includes measurement of blood, urine and CSF amino acids, urine organic acids, blood and CSF lactate/pyruvate levels and very long chain fatty acids in the blood. It is important to obtain CSF because in certain metabolic disorders the biochemical abnormality may be confined to the CSF, as in some of the mitochondrial disorders or in late-presenting non-ketotic hyperglycinaemia, or because the ratio of CSF to blood metabolites could be diagnostic. This is particularly relevant for mitochondrial disorders including Leigh's syndrome where the CSF levels of lactate may be markedly elevated despite normal levels in the plasma; this phenomenon may also be seen between blood and other tissues, including muscle. The phenomenon is explained by mitochrondial DNA heteroplasmy in which different levels of mutant mitochondrial DNA are expressed in different tissues (and body fluids) from the same patient.
In the more slowly progressive metabolic storage and degnerative diseases, tbe general nature of the disorder, and the investigations required, are often suggested by a careful history and clinical examination38*39. Many of these disorders can be confirmed from the reduced or absent activity of the relevant enzyme measured in white blood cells in a supra-regional laboratory. Abnormal storage material may produce a characteristic histological appearance which will be readily identified on biopsy of the skin, rectum or conjunctiva.
Tissue biopsies may atso be required in certain disorders of intermediary metabolism, for example pyruvate enzyme activities can be measured in fibroblasts obtained from a skin biopsy, and individual mitochondrial respiratory chain enzymes can be assayed, and mitocbondrial morphology examined, in a muscle biopsy sample3'.
MANAGEMENT
The detailed management of metabolic disorders can be found in the standard texts previously quoted. In general, when patients present acutely with seizures in association with an encephalopathic illness, due to a disorder of intermediary metabolism, then initial management should be aimed at securing the airway and maintaining adequate respiration and tissue perfusion. A rapid bed-side blood glucose measurement must be obtained. Continuing seizures require urgent antiepileptic drug treatment according to the specific clinical situation and local protocol. If an underlying metabolic disorder is suspected, further biochemical investigations need to be undertaken as previously discussed. Peritoneal dialysis, haemodialysis, haemofiltration or exchange transfusion may be required for severe metabolic acidosis not responding readily to intravenous infusions of sodium bicarbonate, or for severe hyperammonaemia.
The long-term management of amino acidaemias usually requires the dietary restriction of certain amino acids, and low protein diets are required in the organic acidaemias and urea cycle disorders. Prolonged fasting should also be avoided in those children who are at risk from developing hypoglycaemia. Specific dietary supplements may be helpful, either to provide substrates to facilitate alternative metabolic pathways, or to enhance any residual enzyme activity through the administration of high doses of vitamin cofactors, as with thiamine, riboflavine, pyridoxine and vitamins C and K for some of the mitochondrial cytopathies; however, it must be emphasized that the use of these therapies is essentially empirical and their effectiveness largely unproven, although anecdotal (i.e. single case) reports have occasionally suggested some benefit.
There is no consistently effective treatment currently available for metabolic storage disorders. Direct replacement of deficient enzymes has been attempted by means of regular intravascular infusions of the appropriate enzyme and direct gene replacement has been attempted using viral vectors, but with little clinical benefit. Replacement of both the defective enzyme and the respective gene is possible using leucocyte intravascular infusions or bone marrow transplantation. The clinical response following bone marrow transplantation in storage disorders, once neurological signs are established, has been generally disappointing4'.
More encouraging results may be seen if transplantation is undertaken early in the disease process when the child is asymptomatic but shows abnormalities only on psychological testing or neuroimaging, as is currently 'recommended' in severe, childhoodonset adrenoleucodystrophy41.
None of these treatments directly address the enzyme deficiency within the central nervous system but there is hope from animal studies that treating transplanted bone marrow to massively increase production of the deficient enzyme and to encourage infiltration of these cells into the brain may substantially improve the treatment of lysosomal storage disorders4*.
Recurrent seizures occurring in children and adolescents with an underlying metabolic disorder may resolve if the metabolic disorder can be corrected, but otherwise the seizures should be treated with standard antiepileptic drugs. Caution is required when considering the use of phenytoin and particularly valproate in young children with multiple seizure types (particularly myoclonic seizures), in association with developmental delay and suspected disorders of metabolism because of the risk of hepatic necrosis which might, at least in some cases, be due to an inherited metabolic investigation of epilepsy in childhood 199 disorder4M5, which could be 'unmasked' by these drugs. Low levels of plasma carnitine have been documented in some patients with epilepsy receiving sodium valporate/valporic acid; in view of this administration of L-carnitine has been advocated for children with apparent 'valproateassociated hepatotoxicity', and although this has resulted in an increase in plasma levels of free-carnitine, this has not been a consistent finding. In addition, it remains unclear as to whether this biochemical 'improvement' is associated with any significant clinical improvement in the hepatic or overall neurological status of the child, or whether the use of carnitine could actually prevent the hepatotoxicity of sodium valproate46.
In conclusion, metabolic disorders are a relatively uncommon, but important, cause of childhood seizures. Routinely searching for a metabolic disorder, other than hypoglycaemia, in children and adolescents with epilepsy is generally unrewarding.
Instead, biochemical investigations should be reserved for those subjects with epilepsy in whom a metabolic disorder is suspected on considering the seizure type, age of onset, EEG appearance, family history, clinical findings and results of any brain imaging studies. Of these various features, the age of onset, seizure type (usually, but not invariably, myocionic seizures) and the clinical findings are often the most helpful in determining the probability of an underlying metabolic disorder. A few, readily available, biochemical screening tests can broadly categorize the more common metabolic disorders associated with seizures. Further biochemical investigation and management of the suspected metabolic disorder should be undertaken in consultation with those who have experience of such disorders.
